Treating Oxidative Stress in Children With Autism

This study has been completed.
Information provided by:
Arkansas Children's Hospital Research Institute Identifier:
First received: June 4, 2008
Last updated: June 5, 2008
Last verified: June 2008

An open label trial was undertaken in 40 autistic children to determine whether treatment with metabolic precursors methylcobalamin and folinic acid would improve plasma biomarkers of oxidative stress and measures of core behavior using the Vineland Adaptive Behavior Scales (VABS). Metabolites involved in methionine and glutathione synthesis and VABS behavior scores were measured before and after a three month intervention period.

The results indicated that pre-treatment metabolites in autistic children were significantly different from values in age-matched control children. The three month intervention resulted in significant increases in cysteine, cysteinylglycine, and glutathione (GSH, p < 0.001). The oxidized disulfide form of glutathione (GSSG) was decreased (p < 0.008) and the glutathione redox ratio (GSH/GSSG) was increased after treatment (p < 0.001). Although significantly improved, these metabolites remained below control levels after intervention (p > 0.01). Similarly, increases in VABS composite score and sub-scores for Socialization, Communication, and Daily Living Skills increased after treatment (p < 0.007) but also remained below standard scores.

Condition Intervention
Autistic Disorder
Dietary Supplement: Methylcobalamin (methylB12)
Dietary Supplement: Folinic acid

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Efficacy of Methylcobalamin and Folinic Acid Treatment on Glutathione Redox Status and Core Behavior in Children With Autism

Resource links provided by NLM:

Further study details as provided by Arkansas Children's Hospital Research Institute:

Primary Outcome Measures:
  • Glutathione redox status (GSH/GSSG) [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Vineland Adaptive Behavior Scales [ Designated as safety issue: No ]

Enrollment: 40
Study Start Date: September 2006
Study Completion Date: December 2007
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Dietary Supplement: Methylcobalamin (methylB12)
    75 ug/Kg methylB12 every 3 days by subcutaneous injection
    Other Name: Vitamin B12
    Dietary Supplement: Folinic acid
    400 ug b.i.d.
    Other Name: Leucovorin

Ages Eligible for Study:   3 Years to 7 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of Autistic Disorder by DSM-IV 299.0 or CARS score >30

Exclusion Criteria:

  • Primary genetic disease with co-morbid autism
  • frequent seizures
  • recent surgery
  • active infection with fever
  • high dose vitamin/mineral supplements
  • severe gastrointestinal symptoms
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00692315

United States, Arkansas
Arkansas Children's Hospital Research Institute
Little Rock, Arkansas, United States, 72202
Sponsors and Collaborators
Arkansas Children's Hospital Research Institute
Principal Investigator: S. Jill James, PhD University of Arkansas
  More Information

No publications provided by Arkansas Children's Hospital Research Institute

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: S. Jill James, Arkansas Children's Hospital Research Institute Identifier: NCT00692315     History of Changes
Other Study ID Numbers: 28839 
Study First Received: June 4, 2008
Last Updated: June 5, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by Arkansas Children's Hospital Research Institute:
folinic acid
oxidative stress

Additional relevant MeSH terms:
Autistic Disorder
Child Development Disorders, Pervasive
Mental Disorders
Mental Disorders Diagnosed in Childhood
Folic Acid
Vitamin B 12
Growth Substances
Hematologic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Vitamin B Complex
Vitamins processed this record on February 10, 2016